Zhang J, et al. - Researchers assess the efficacy and safety of conbercept in the treatment of wet age-related macular degeneration (AMD) via performing a systematic review. On analyzing 18 randomized controlled trials (RCTs) (1285 participants), conbercept seemed efficacious in improving best-corrected visual acuity (BCVA) compared to triamcinolone acetonide, and reducing central retinal thickness (CRT) compared to the other four therapies (conservative treatment, ranibizumab, transpupillary thermotherapy, and triamcinolone acetonide). Hence, conbercept has been recognized as a promising option for the treatment of wet AMD.